MLH1 and colorectal cancer: Though not all studies agree, most clinical findings indicate MLH1 and MSH2 deficiencies contribute to poorer outcomes with 5-FU treatment for colorectal cancer (Ribic et al., 2003; Sargent et al., 2010).